Skip to main content
Industry News
Glycostem's multiple myeloma therapy gains orphan tag

Glycostem Therapeutics' natural killer cell-based therapy oNKord was granted orphan drug designation by the FDA as a treatment for multiple myeloma. The treatment was also granted orphan drug status in 2016 to treat adults diagnosed with acute myeloid leukemia.

Full Story: